Soleno Therapeutics (NASDAQ:SLNO) Downgraded to Hold Rating by Wall Street Zen

Soleno Therapeutics (NASDAQ:SLNO) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

A number of other equities research analysts have also commented on SLNO. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price (up from $110.00) on shares of Soleno Therapeutics in a research report on Tuesday, January 20th. Zacks Research cut shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. TD Cowen cut their price objective on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a report on Tuesday, January 13th. Finally, Wolfe Research set a $60.00 price target on shares of Soleno Therapeutics in a report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $108.38.

Soleno Therapeutics Price Performance

Shares of SLNO opened at $39.07 on Friday. The firm has a market capitalization of $2.02 billion, a PE ratio of 169.88 and a beta of -3.16. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88. Soleno Therapeutics has a 1-year low of $32.63 and a 1-year high of $90.32. The company’s fifty day moving average price is $42.63 and its 200-day moving average price is $53.54.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to analysts’ expectations of $88.55 million. On average, equities research analysts predict that Soleno Therapeutics will post -3.72 EPS for the current year.

Institutional Trading of Soleno Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Soleno Therapeutics by 1.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after acquiring an additional 189 shares during the period. Goldman Sachs Group Inc. raised its holdings in Soleno Therapeutics by 50.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company’s stock worth $45,236,000 after purchasing an additional 213,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Soleno Therapeutics by 48.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company’s stock worth $2,909,000 after purchasing an additional 13,211 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Soleno Therapeutics by 287.8% during the second quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock worth $45,000 after purchasing an additional 400 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its position in shares of Soleno Therapeutics by 32.9% in the second quarter. Envestnet Asset Management Inc. now owns 5,866 shares of the company’s stock valued at $491,000 after buying an additional 1,453 shares in the last quarter. Institutional investors and hedge funds own 97.42% of the company’s stock.

Key Headlines Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Earnings beat and profitability: Soleno reported Q4 2025 EPS of $0.80 (vs. $0.64 consensus) and revenue of $91.73M (vs. $88.55M), and management highlighted achieving profitability — the core reason investors are bidding the stock up. Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Full earnings/transcript availability: Multiple transcripts and call write-ups (Seeking Alpha, Yahoo) give investors detailed color on guidance, margins and cash flow — useful for conviction but not immediate catalysts. Q4 2025 Earnings Call Transcript Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Wells Fargo cut its price target slightly from $114 to $110 but kept an Overweight rating — this is a modest headwind but still signals strong upside from analysts. Wells Fargo price-target note
• Negative Sentiment: TD Cowen substantially lowered its target (from $120 to $85) despite maintaining a Buy rating — the larger cut adds downward pressure to headline analyst sentiment and may temper the rally. TD Cowen price-target change
• Negative Sentiment: Near-term volatility / profit-taking explained: Coverage and commentary note a sharp intraday decline (reported as ~10.8% in one write-up) after the earnings run-up — investors appear to be re‑rating the name on guidance details, forward EPS expectations, and valuation. Why SLNO Stock Is Down 10.80%

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.